News

In April CMS released final rules outlining significant updates to the Medicaid managed care program. Here are the top issues to watch.

Analysis from Prime shows that improvements in persistency, adherence is key in RA treatments.

What is the future of Healthcare Exchanges? And what is the future of Obamacare in general? Healthcare executives weigh in.

Biosimilars in the United States are slowly gaining traction, but widespread confusion and legal barriers remain.

While healthcare has flown under the radar for much of this election season, it’s a topic that was not ignored at the Academy of Managed Care Pharmacy (AMCP) Nexus in National Harbor, Maryland.

Promising treatments are coming for alopecia areata and atopic dermatitis, but they will come at a high cost.

A comprehensive understanding of this rapidly increasing drug class is essential to integrate pharmacy and medical claim information.

Approvals of specialty pharmaceuticals have far outpaced traditional drugs, and that trend will continue. But that’s not the only specialty medication trend that healthcare executives should have on their radar.

Understanding both candidates proposals can help executives make informed decisions.

Biomarkers, if used appropriately, could ensure patients receive the appropriate treatment sooner, and that they have better outcomes at reduced costs. But despite the potential and expanding capabilities, barriers to full-fledged use remain.

Here are the top 10 states that deliver the best healthcare services, according to personal-finance website WalletHub.

As the opioid epidemic continues across the U.S., new treatment programs and guidelines could help reverse the trend.

In 2014, nearly 2 million Americans met the diagnostic criteria for a past-year prescription opioid use disorder, and at least 14,000 people died from a prescription opioid overdose. Read about the top drivers and risk factors.

Two reports highlight areas of elderly care that healthcare systems and health plans should avoid.

FDA recently expanded the use of lumacaftor/ivacaftor (Orkambi, Vertex Pharmaceuticals) to treat cystic fibrosis in children aged 6 to 11 years who have two copies of the F508del mutation.

An independent study considers the global adoption of value-based healthcare across 25 countries.

Five key areas of healthcare, the candidates’ proposals for them, and analysis from experts.

The use of advanced analytics by payers can improve administrative and medicalcosts, provider satisfaction and member health.

FDA recently approved several medications and devices across several therapy areas: diabetes, weight loss and rare, auto-inflammatory diseases. Here are the top 3 new approvals.

A report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.

NIH-funded study shows less diabetic retinopathy progression among those who underwent intensive glycemic control.

IMS Health study: Up to 15% of healthcare system costs avoidable and effective patient activation by multiple stakeholders is key to driving improvement.

Find out where each presidential candidate stands on key issues related to pharmaceutical costs.

Humana and UCS study shows prevalence of ageism in film and the power of embracing a healthy mindset for healthy aging

Migration to high-deductible plans partly responsible, according to Kaiser Family Foundation survey.

FDA’s pace of biosimilar approvals is picking up, as it approved two major drugs for rheumatoid arthritis and other inflammatory diseases in the past month.

FDA recently approved an expanded use for Invokamet (Janssen): Invokamet XR, an extended-release combination drug to treat type 2 diabetes. The original Invokamet was approved by FDA in 2014.

To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, conducted its first-ever pharmacy survey during the second quarter of 2016.

When is retail right? Consider these four benefits that will impact the bottom line.

HHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.